eledon-logo-1230.png
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
04. März 2025 16:05 ET | Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
eledon-logo-1230.png
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
07. Februar 2025 10:00 ET | Eledon Pharmaceuticals, Inc.
Eledon Announces Tegoprubart Use as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
eledon-logo-1230.png
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
29. Januar 2025 16:05 ET | Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Participate in Guggenheim SMID Cap Biotech Conference
eledon-logo-1230.png
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
13. Januar 2025 07:00 ET | Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
eledon-logo-1230.png
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
12. November 2024 16:01 ET | Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
eledon-logo-1230.png
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
06. November 2024 16:05 ET | Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
eledon-logo-1230.png
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
29. Oktober 2024 07:46 ET | Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
eledon-logo-1230.png
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
29. Oktober 2024 07:45 ET | Eledon Pharmaceuticals, Inc.
Eledon Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of Regimen Following Islet Transplantation
eledon-logo-1230.png
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
11. September 2024 16:05 ET | Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
eledon-logo-1230.png
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
04. September 2024 07:00 ET | Eledon Pharmaceuticals, Inc.
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplants